First-and-Best LeadWide moat

In the incretin race, Lilly enjoys the advantage of being both early and, by most measures, best. Its tirzepatide acts on two gut hormones rather than one¹, and in comparative data it has generally produced greater weight loss than the single-hormone drugs, giving Lilly a genuine clinical edge in the most important dimension — efficacy — of the most important drug market in the world. Being first with a demonstrably superior product is the strongest possible position in pharmaceuticals.

The lead compounds through the head start it confers. Being early meant Lilly captured demand, built prescriber relationships, and generated the real-world evidence and expanded indications that entrench a drug, all before most rivals arrived. Being best meant that when patients and doctors chose, they had a reason to choose Lilly, and superior efficacy is a durable differentiator in a field where results are measurable and matter enormously. Together, first-and-best gave Lilly a lead that late entrants must overcome rather than merely match.

The caveat is that first-and-best is a lead, not a monopoly, in a class that will grow crowded. Novo Nordisk is a formidable, well-established competitor with its own blockbuster incretins; a wave of next-generation drugs from many companies is coming; and clinical leads can be overtaken as rivals develop their own superior molecules. So Lilly's first-and-best position is a real and valuable advantage that has let it seize the lead in a generational market — but one it must defend with continued innovation, because in drug development, today's best is always the target of tomorrow's challengers.